阿尔茨海默症其新药研发失败率高达99.6%。昨天我们分享了两家失败的药物Simufilam和AL002，其 针对的靶点较为新颖。今日我们就其靶点和数据进行分析。

US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...

Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of ...

南旧金山 - 专注于神经退行性疾病的生物科技公司Alector, Inc.

(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 ...

Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

周二，高盛重申了对Alector Inc. (NASDAQ:ALEC)股票的卖出评级，维持4.00美元的目标价。关注点集中在即将公布的INVOKE-2研究的第二阶段结果，该研究正在评估Alector的AL002用于治疗阿尔茨海默病。高盛对该资产和研究提供了深入的背景分析，预览了可能的结果，并讨论了这些结果对公司估值的潜在影响。

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...